The rotavirus vaccine development pipeline

Carl D. Kirkwood*, Lyou Fu Ma, Megan E. Carey, A. Duncan Steele

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

83 Citations (Scopus)


Rotavirus disease is a leading global cause of mortality and morbidity in children under 5 years of age. The effectiveness of the two globally used oral rotavirus vaccines quickly became apparent when introduced into both developed and developing countries, with significant reductions in rotavirus-associated mortality and hospitalizations. However, the effectiveness and impact of the vaccines is reduced in developing country settings, where the burden and mortality is highest. New rotavirus vaccines, including live oral rotavirus candidates and non-replicating approaches continue to be developed, with the major aim to improve the global supply of rotavirus vaccines and for local implementation, and to improve vaccine effectiveness in developing settings. This review provides an overview of the new rotavirus vaccines in development by developing country manufacturers and provides a rationale why newer candidates continue to be explored. It describes the new live oral rotavirus vaccine candidates as well as the non-replicating rotavirus vaccines that are furthest along in development.

Original languageEnglish
Pages (from-to)7328-7335
Number of pages8
Issue number50
Publication statusPublished - 28 Nov 2019
Externally publishedYes


  • Non-replicating
  • Rotavirus
  • Vaccines


Dive into the research topics of 'The rotavirus vaccine development pipeline'. Together they form a unique fingerprint.

Cite this